New Delhi: The government is making all efforts to support and promote development of vaccine for COVID-19. However, there is a need to strengthen cold chain logistics and remove COVID-19 vaccine hesitancy, experts said Wednesday.
Currently in India, there are more than 30 groups both from academia and industry that are actively involved in development of COVID-19 vaccines. There are six vaccine candidates in various stages of clinical trials, out of which four are developed indigenously. This information was shared by Department of Biotechnology Scientist and Adviser Asha Sharma.
“The government is facilitating the capacity enhancement for strengthening the ecosystem across India to promote and support vaccine development,” Sharma said. Her comments came while participating in the discussion on ‘Economics and Logistics of a Vaccine Response’ at the CII Partnership Summit 2020.
In order to strengthen the ecosystem, 11 good clinical practices compliant clinical trial sights have also been established across India, Sharma said. The government is making purposeful and integrated efforts to support and promote vaccine development for COVID-19, she added.
IHH Healthcare Berhad Group Head of Operations and Integration Ashok Bajpai said India has a very good existing infrastructure of administration of mass doses. However, cold chain logistics requires to be strengthened.
“I am not worried about the physical process of distribution and administration. I actually worry about the cold chain logistics and loss of efficacy of the vaccine as we distribute it into the heartland of India, where we have relatively poor infrastructure,” said Bajpai.
Sanofi Pasteur, India Country Head, Annapurna Das emphasised on the need for information, education and communication especially in these times. She however highlighted that India has a good blueprint in terms of cold chain and healthcare workers capacity and that the entire framework is quite digitally enabled.
There is a need for community education information programme to remove the vaccine hesitancy, as it is a reality and also minimizing vaccine wastage, Das said.
